⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21737618 | 0.79 | — | — | |
| SCHEMBL8545497 | 0.76 | — | — | |
| SCHEMBL1569387 | 0.76 | — | — | |
| SCHEMBL7351094 | 0.74 | CYP2A6 (0.38) | — | |
| SCHEMBL29545244 | 0.74 | HTT (0.39) | — | |
| SCHEMBL454920 | 0.73 | — | — | |
| SCHEMBL10298261 | 0.73 | — | — | |
| SCHEMBL27371448 | 0.73 | — | — | |
| SCHEMBL462745 | 0.71 | SLC5A2 (0.47) | — | |
| SCHEMBL12440891 | 0.70 | ALOX5 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150340-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED | 2024-05-09 | — | — | US | disclosed |
| WO-2024077216-A1 | CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS INCORPORATED (US) | 2024-04-11 | — | — | WO | disclosed |
| WO-2024077216-A1 | CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS INCORPORATED (US) | 2024-04-11 | — | — | WO | disclosed |
| EP-3555078-B1 | BISARYL HETEROCYCLES AS NRF2 ACTIVATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2024-03-27 | — | — | EP | disclosed |
| US-11117905-B2 | Bisaryl heterocycles as NRF2 activators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-09-14 | — | — | US | disclosed |
| US-11117905-B2 | Bisaryl heterocycles as NRF2 activators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-09-14 | — | — | US | disclosed |
| US-20200062781-A1 | BISARYL HETEROCYCLES AS NRF2 ACTIVATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2020-02-27 | — | — | US | disclosed |
| US-20200062781-A1 | BISARYL HETEROCYCLES AS NRF2 ACTIVATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2020-02-27 | — | — | US | disclosed |
| EP-3555078-A1 | BISARYL HETEROCYCLES AS NRF2 ACTI | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2019-10-23 | — | — | EP | disclosed |
| WO-2018109643-A1 | BISARYL HETEROCYCLES AS NRF2 ACTI | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-06-21 | — | — | WO | disclosed |
| WO-2018109643-A1 | BISARYL HETEROCYCLES AS NRF2 ACTI | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-06-21 | — | — | WO | disclosed |
| WO-2012033390-A2 | NOVEL THIOPHENE DERIVATIVE AS SGLT2 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2012-03-15 | — | — | WO | disclosed |